Genetic variants in selenoprotein P plasma 1 gene (SEPP1) are associated with fasting insulin and first phase insulin response in Hispanics

Gene

Volumn 534, Issue 1, 2014, Pages 33-39

  Hellwege, Jacklyn N ^a   Palmer, Nicholette D ^a   Ziegler, Julie T ^a   Langefeld, Carl D ^a   Lorenzo, Carlos ^b   Norris, Jill M ^c   Takamura, Toshinari ^d   Bowden, Donald W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b University of Texas Health Science Center   (United States)

^c Food Science and Human Nutrition   (United States)

^d KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Acute insulin response (AIR); Fibrinogen; Hispanic Americans; Insulin resistance; Selenium; Selenoproteins

Indexed keywords

GLUCOSE; INSULIN; SELENOPROTEIN P;

ADULT; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HISPANIC; HUMAN; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AA; ACUTE INSULIN RESPONSE; ACUTE INSULIN RESPONSE (AIR); AFRICAN AMERICAN; AIR; APOB; APOLIPOPROTEIN B; BMI; BODY MASS INDEX; DI; DISPOSITION INDEX; EA; EUROPEAN AMERICAN; FIBRINOGEN; FREQUENTLY SAMPLED INTRAVENOUS GLUCOSE TOLERANCE TEST; FSIGT; HA; HDL; HIGH-DENSITY LIPOPROTEIN; HISPANIC AMERICAN; HISPANIC AMERICANS; HOMA-IR; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; IL6; INSULIN RESISTANCE; INSULIN RESISTANCE ATHEROSCLEROSIS FAMILY STUDY; INSULIN RESISTANCE ATHEROSCLEROSIS STUDY; INSULIN SENSITIVITY INDEX; INTERLEUKIN 6; IRAS; IRASFS; LDL; LOW-DENSITY LIPOPROTEIN; MAF; MCRI; METABOLIC CLEARANCE RATE OF INSULIN; MINOR ALLELE FREQUENCY; PAI-1; PLASMINOGEN ACTIVATOR INHIBITOR-1; S(I); SAT; SELENIUM; SELENOPROTEIN P; SELENOPROTEINS; SEP; SEQUENTIAL OLIGOGENIC LINKAGE ANALYSIS ROUTINES; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SOLAR; SUBCUTANEOUS ADIPOSE TISSUE; T2D; TNF; TUMOR NECROSIS FACTOR; TYPE 2 DIABETES MELLITUS; UNTRANSLATED REGION; UTR; VAT; VISCERAL ADIPOSE TISSUE; WAIST:HIP RATIO; WHR;

ADULT; COHORT STUDIES; FASTING; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HISPANIC AMERICANS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SELENOPROTEIN P;

MUS;

EID: 84888056259     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.10.035     Document Type: Article

References (45)

1. Almasy L., Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am. J. Hum. Genet. 1998, 62:1198-1211.
2. Ballihaut G., Kilpatrick L., Kilpatrick E., Davis W. Multiple forms of selenoprotein P in a candidate human plasma standard reference material. Metallomics 2012, 4:533-538.
3. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
4. Beckett G.J., Arthur J.R. Selenium and endocrine systems. J. Endocrinol. 2005, 184:455-465.
5. Brocheriou I., et al. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis 2011, 214:316-324.
6. Bruno G., et al. Hyperfibrinogenemia and metabolic syndrome in type 2 diabetes: a population-based study. Diabetes Metab. Res. Rev. 2001, 17:124-130.
7. Burk R.F., Hill K.E., Motley A.K. Plasma selenium in specific and non-specific forms. Biofactors 2001, 14:107-114.
8. Can B., Ulusu N.N., Kilinç K., Leyla Acan N., Saran Y., Turan B. Selenium treatment protects diabetes-induced biochemical and ultrastructural alterations in liver tissue. Biol. Trace Elem. Res. 2005, 105:135-150.
9. Choi H.Y., et al. Increased selenoprotein p levels in subjects with visceral obesity and nonalcoholic fatty liver disease. Diabetes Metab. J. 2013, 37:63-71.
10. Dreher I., Jakobs T.C., Kohrle J. Cloning and characterization of the human selenoprotein P promoter. Response of selenoprotein P expression to cytokines in liver cells. J. Biol. Chem. 1997, 272:29364-29371.
11. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: ) [September 2011]. http://http://evs.gs.washington.edu/EVS/.
12. Ferguson L.R., Karunasinghe N., Zhu S., Wang A.H. Selenium and its' role in the maintenance of genomic stability. Mutat. Res. 2012, 733:100-110.
13. Gabriel S., Ziaugra L., Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr. Protoc. Hum. Genet. 2009, 12. (Chapter 2, Unit 2).
14. Ganda O.P., Arkin C.F. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care 1992, 15:1245-1250.
15. Goodrich J.M., Wang Y., Gillespie B., Werner R., Franzblau A., Basu N. Glutathione enzyme and selenoprotein polymorphisms associate with mercury biomarker levels in Michigan dental professionals. Toxicol. Appl. Pharmacol. 2011, 257:301-308.
16. Henkin L., et al. Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann. Epidemiol. 2003, 13:211-217.
17. Hill K.E., Lloyd R.S., Burk R.F. Conserved nucleotide sequences in the open reading frame and 3' untranslated region of selenoprotein P mRNA. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:537-541.
18. Hill K.E., et al. Deletion of selenoprotein P alters distribution of selenium in the mouse. J. Biol. Chem. 2003, 278:13640-13646.
19. International HapMap Project International HapMap Project. Nature 2003, 426(6968):789-796.
20. Jung T.W., et al. Salsalate and adiponectin improve palmitate-induced insulin resistance via inhibition of selenoprotein P through the AMPK-FOXO1alpha pathway. PLoS One 2013, 8:e66529.
21. Karunasinghe N., et al. Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr. 2012, 7:179-190.
22. Mao J., Teng W. The relationship between selenoprotein P and glucose metabolism in experimental studies. Nutrients 2013, 5:1937-1948.
23. Méplan C., Hesketh J. The influence of selenium and selenoprotein gene variants on colorectal cancer risk. Mutagenesis 2012, 27:177-186.
24. Meplan C., et al. Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). FASEB J. 2007, 21:3063-3074.
25. Meplan C., et al. Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid. Redox Signal. 2009, 11:2631-2640.
26. Misu H., et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010, 12:483-495.
27. Misu H., et al. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS One 2012, 7:e34952.
28. Mostert V., Lombeck I., Abel J. A novel method for the purification of selenoprotein P from human plasma. Arch. Biochem. Biophys. 1998, 357:326-330.
29. O'Connell J.R., Weeks D.E. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am. J. Hum. Genet. 1998, 63:259-266.
30. Palmer N.D., et al. Candidate loci for insulin sensitivity and disposition index from a genome-wide association analysis of Hispanic participants in the Insulin Resistance Atherosclerosis (IRAS) Family Study. Diabetologia 2010, 53:281-289.
31. Penney K.L., et al. Selenoprotein P genetic variants and mRNA expression, circulating selenium, and prostate cancer risk and survival. Prostate 2013, 73(7):700-705.
32. Purcell S., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
33. Rayman M.P., Stranges S. Epidemiology of selenium and type 2 diabetes: can we make sense of it?. Free Radic. Biol. Med 2013, [Epub ahead of print]. 10.1016/j.freeradbiomed.2013.04.003.
34. Schwarz K., Foltz C. Factor 3 activity of selenium compounds. J. Biol. Chem. 1958, 233:245-251.
35. Slattery M.L., Lundgreen A., Welbourn B., Corcoran C., Wolff R.K. Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. PLoS One 2012, 7:e37312.
36. Stapleton S.R. Selenium: an insulin-mimetic. Cell Mol. Life Sci. 2000, 57:1874-1879.
37. Stranges S., et al. Selenium status and blood lipids: the cardiovascular risk in Young Finns study. J. Intern. Med. 2010, 270:469-477.
38. Stranges S., et al. Associations of selenium status with cardiometabolic risk factors: an 8-year follow-up analysis of the Olivetti Heart study. Atherosclerosis 2011, 217:274-278.
39. Takata Y., et al. Genetic variation in GPX1 is associated with GPX1 activity in a comprehensive analysis of genetic variations in selenoenzyme genes and their activity and oxidative stress in humans. J. Nutr. 2012, 142:419-426.
40. Wagenknecht L.E., et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann. Epidemiol. 1995, 5:464-472.
41. Willer C.J., Li Y., Abecasis G.R. METAL: fast and efficient meta-analysis of genome wide association scans. Bioinformatics 2010, 26:2190-2191.
42. Xia Y., Hill K., Byrne D., Xu J., Burk R. Effectiveness of selenium supplements in a low-selenium area of China. Am. J. Clin. Nutr. 2005, 81:829-834.
43. Yang S.J., et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J. Clin. Endocrinol. Metab. 2011, 96:E1325-E1329.
44. Zeng M.S., et al. A high-selenium diet induces insulin resistance in gestating rats and their offspring. Free Radic. Biol. Med. 2012, 52:1335-1342.
45. Zhang Y., Chen X. Reducing selenoprotein P expression suppresses adipocyte differentiation as a result of increased preadipocyte inflammation. Am. J. Physiol. Endocrinol. Metab. 2010, 300:E77-E85.